Eligard® (Leuprolide Acetate)
| Manufacturer: Sanofi-Aventis |
| General Information: Eligard® is typically utilized for
the pallative treatment of prostate cancer. For
indication,dosing or other information, please refer to the
manufacture package insert. |
| |
|
Product |
Size |
NDC Number |
PI |
MSDS |
| Eligard® |
7.5 mg |
00024-0793-75 |
PI |
MSDS |
| Eligard® |
22.5 mg |
00024-0222-05 |
PI |
MSDS |
| Eligard® |
30 mg |
00024-0610-30 |
PI |
MSDS |
| Eligard® |
45 mg |
00024-0605-45 |
PI |
MSDS |
|
| |
| Clinical
Data: For any questions
or for further information
related to Eligard®, clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and / or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |